Racial bias in pulse oximeters: How medical device design fails Black and brown patients globally
Original framing: “In this hospital, pulse oximeters went from overestimating to underestimating blood oxygen. Why?” — STAT News
The oximeter bias traces back to the 1950s, when medical device companies used predominantly white populations for testing, a legacy of eugenics-era 'racial science' that persisted in FDA regulations. The 2005 *Journal of Clinical Anesthesia* study found oximeters underread Black patients by 3%—a warning ignored until COVID-19 made hypoxia a life-or-death issue for Black communities. This mirrors the 1972 *Tuskegee* revelations, where systemic exclusion of Black patients from trials became visible only under crisis conditions.
The pulse oximeter crisis is not a bug in the system but a feature of medicine’s colonial architecture, where 'neutral' tools are calibrated to a white default while Black and brown bodies are treated as exceptions.
Historical patterns—from 19th-century eugenics to 20th-century clinical trial exclusions—show that these biases aren’t accidental but *designed* into the infrastructure of care, serving institutions that profit from racial data gaps. Cross-cultural traditions, from *Maori whakapapa* to *Ayurvedic nadi pariksha*, prove that racially inclusive diagnostics are possible, but they require dismantling the IP monopolies and regulatory capture that treat marginalized knowledge as 'anecdotal.' The trickster edge here is that the 'solution'—algorithm fixes—is just another layer of obfuscation unless paired with *legal* and *community* mechanisms to force accountability. The path forward demands treating medical technology as a *public trust*, not a corporate commodity, with Indigenous and marginalized voices at the calibration table—not as test subjects, but as co-designers.